Gaysin Malik Fawzavievich

Gaysin Malik Fawzavievich

Biography

2023: Withdrawal of Uralbiopharm shares in favor of the state

In mid-August 2023, the Leninsky District Court of Yekaterinburg satisfied the claim of the Deputy Prosecutor General of the Russian Federation Igor Tkachev and seized from the former State Duma deputy Malika Gaysin the shares of the Uralbiopharm company worth 3 billion rubles in favor of the state.

The Prosecutor General's Office believes that in the period from 1995 to 1999. Gaysin, being a deputy of the State Duma, at the same time - in violation of anti-corruption bans - was engaged in entrepreneurial activities. In particular, he personally and through proxies bought up shares in Uralbiopharm OJSC, as a result of which he became the monopoly owner of the organization with a beneficial interest of 99.995%.

To avoid problems with the law, Malik Gaysin established two companies: Vagran LLC and Aktay-M LLC, for which he issued shares in Uralbiofarm (each has a 24.9% stake in Uralbiofarm), Igor Tkachev is sure. Shares in the authorized capital of these firms are also subject to withdrawal.

According to Gaysin himself, in 30 years of open ownership of assets by regulators, there were no claims against him. He claims to have bought shares during privatisation at check auctions and from individuals. He suspects that the lawsuit against him is filed "in the interests of individuals."

In the spring of 2023, the chief technologist of Uralbiofarm Marina Chizhova appealed to the authorities with a proposal to index prices for drugs from the VED list once a year - to the inflation rate. She explained that the cost of most of the drugs is higher than the maximum prices set by the state, in connection with which the company is sometimes forced to refuse to produce some products.

There is nothing surprising in the Gaysin case - the process of illegal enrichment took place in the 90s almost everywhere, Kirill Kabanov, chairman of the National Anti-Corruption Committee, told Izvestia. Public property often passed into private hands illegally. This probably happened with the Sverdlovsk pharmaceutical plant, which in 1996 was privatized and renamed Uralbiopharm OJSC, he suggested.^[1]

Notes